Company news

ALX Oncology Holdings Inc. news in 2020

ALX Oncology Holdings Inc.'s news releases, calls and decks from 2020, newest first.

View company

ALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

December 13, 2020

ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock

December 8, 2020

ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies

December 6, 2020

ALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma

December 6, 2020

ALX Oncology Announces Proposed Public Offering of Common Stock

December 6, 2020

ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights

November 11, 2020

ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors

November 8, 2020

ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome

October 27, 2020

ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board

October 5, 2020

ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head & Neck Cancer

September 21, 2020

ALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical Highlights

August 26, 2020

ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

July 20, 2020

ALX Oncology Announces Pricing of Initial Public Offering

July 15, 2020